Biomineralization Hypothesis

Scientific Definition

The Biomineralization Hypothesis proposes that the same bacterial extracellular vesicle pathways driving soft-tissue pathology — atherosclerosis, neuroinflammation — also mediate pathological calcification: vascular calcification, cardiac valve calcification, and potentially amyloid nucleation.

The hypothesis rests on three observations:

1. bEVs from oral bacteria carry alkaline phosphatase and calcium-binding proteins that are structurally homologous to the matrix vesicles driving physiological bone mineralization. The machinery is the same. The location is wrong.

1. Atherosclerotic plaque calcification colocalizes with bacterial DNA signatures matching subgingival species. The bacteria — or more precisely, their vesicle cargo — are at the scene.

1. The transition from soft plaque to calcified plaque follows a vesicle-mediated mineralization program indistinguishable in mechanism from intramembranous ossification. Lipid-rich vesicles nucleate hydroxyapatite crystals. This is what matrix vesicles do in bone. It is what bEVs appear to do in arteries.

If correct, the hypothesis unifies soft-tissue and hard-tissue oral-systemic pathology under a single vesicle-mediated program. Inflammation and calcification are not separate disease processes — they are sequential outputs of the same vesicle cascade operating in the same vascular bed.

The prediction is specific and testable, and the choice of endpoint is the whole discipline of it. Calcium burden is the wrong readout: denser coronary calcium is associated with lower event risk per unit density (Criqui, JAMA 2014), so a therapy that reduced calcium score could not be interpreted. The right readout is mineralisation activity — the program running, not the mineral already laid down. Test it via ¹⁸F-NaF PET (active microcalcification, CRP-independent) paired with periodontal charting, serum calcification propensity (T50) as the cheap scalable proxy, vesicle proteomics (ALP activity in circulating bEV fractions), and interventional studies asking whether intensive periodontal therapy reduces ¹⁸F-NaF uptake over 12 months. This is the same falsification target set out in the Xenonucleation artifact. The hypothesis generates protocols. That is the point.

Clinical Definition

The Biomineralization Hypothesis connects two things cardiologists measure — plaque inflammation and plaque calcification — to the same oral source. Your patient's vascular calcification may be driven by the same bacterial vesicles causing their periodontal bone loss. The mechanism is the same: vesicle-mediated mineral deposition. Matrix vesicles build bone. Bacterial vesicles build arterial calcium.

This opens a clinical conversation between periodontists and cardiologists that hasn't existed before. Not "periodontal disease is associated with heart disease" — that's been said for decades and changed nothing. Instead: "the vesicle-mediated mineralization pathway operating in your patient's jaw is also operating in their coronary arteries, and we can measure both." If validated, mineralisation activity imaging — not calcium score — becomes a periodontal outcome measure. The distinction matters clinically: calcium burden tracks the stable, consolidated mineral, while ¹⁸F-NaF uptake tracks the mineral being laid down now. None of this is validated; it is the experiment the hypothesis is written to justify.

B2B Definition

Vascular calcification and periodontal bone loss may share a mechanism. If the Biomineralization Hypothesis holds, periodontal treatment becomes relevant to cardiac risk stratification — a conversation your DSO can own before competitors understand it exists. Early mover advantage in oral-systemic cardiology integration. The practices that can articulate this mechanism to referring physicians and payer medical directors will define the category. Everyone else will follow.